Diabetic Neuropathy Treatment: World Market 2018-2028 - Visiongain Report

Wednesday, April 25, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, April 25, 2018 /PRNewswire/ --

Analysis and Forecasts by Disorder (Peripheral,

Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

)

Report Details  

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 215-page report  you will receive 85 tables and 90 figures- all unavailable elsewhere.

The 215-page report provides clear detailed insight into the Global Diabetic Neuropathy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Diabetic Neuropathy Market forecasts from 2018-2028

• This report breaks down the revenue forecast of the Global Diabetic Neuropathy market into these leading segments:   • By Disorder: • Peripheral Neuropathy • Autonomic Neuropathy • Proximal Neuropathy • Focal Neuropathy

• By Treatment: • Drugs • Anti-Depressants • Anti-Convulsant • Radiotherapy • Physiotherapy 

• By End User: • Hospitals • Clinics • Pharmacy 

Each submarket is further divided by region: North America, South America, Europe, Asia-Pacific and RoW

• This report provides individual revenue forecasts to 2028 for these regional and national markets: North America: the US, Canada, Mexico South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America Europe: Germany, France, the UK, Spain, Italy, Russia, Rest of Europe Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific • Rest of the World: Middle East, Africa, Other Countries

• Our study provides a SWOT analysis and Porter's Five Forces analysis of the Global Diabetic Neuropathy market

• This report discusses the leading companies in the Global Diabetic Neuropathy market • Abbott Laboratories • F. Hoffmann-La Roche Ltd. • Eli Lilly and Company • Johnson & Johnson • GlaxoSmithKline plc. • Lupin Limited • Glenmark Pharmaceuticals Limited • Depomed, Inc. • Astellas Pharma Inc. • Pfizer Inc.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Diabetic Neuropathy Market. You find data, trends and predictions.

Buy our report today Diabetic Neuropathy Treatment: World Market 2018-2028: Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on: https://www.visiongain.com/Report/2175/Diabetic-Neuropathy-Treatment-World-Market-2018-2028

Companies Mentioned in the Report 

Abbott Laboratories

AbbVie, Inc.

Alkermes Plc

Amarin Corp. Plc

Amgen, Inc.

Amnis Corporation

Array BioPharma, Inc.

Associates Of Cape Cod  Inc.

Astex Pharmaceuticals  Inc.

AstraZeneca Plc

ASYMPTOTE LTD

Atom Medical Corporation

Bayer AG

Bayer Corporation

Bayer HealthCare AG

Bayer Schering Pharma Aktiengesellschaft

BioLife Solutions, Inc.

BioMarin Pharmaceutical, Inc.

Biotest AG

Bristol-Myers Squibb Co.

Cardax, Inc.

Cardinal Health, Inc.

Ceapro, Inc.

Celgene Corp.

Cephalon, Inc.

Chugai Pharmaceutical Co., Ltd.

CK Life Sciences International (Holdings), Inc.

Consensys Imaging Service  Inc.

Cornerstone Research & Development  Inc.

Crescendo Bioscience, Inc.

CTI BioPharma Corp.

Deroyal Industries  Inc.

Domain Therapeutics SA

Emd Millipore Corporation

Emd Serono  Inc.

Endo International Plc

European Medicines Agency

Evotec AG

Galderma Sa

GE HEALTHCARE LTD

GlaxoSmithKline Plc

Henry Schein, Inc.

Herbert Waldmann GmbH & Co. KG

Illumina, Inc.

Institut Bergonie

Janssen Biotech, Inc.

JHL Biotech, Inc.

Johnson & Johnson

Laboratoire Theramex

Laboratory Corp. of America Holdings

LifeWatch AG

Lombard Medical, Inc.

Lonza Group AG

McKesson Corp.

Medline Industries  Inc.

Medtronic Plc

Merck KGaA

MorphoSys AG

Motion Picture And Television Fund

Myrexis, Inc.

Myriad Genetics, Inc.

National Biological Corp.

National Cancer Institute

Natus Medical Incorporated

NBTY, Inc.

Neptune Technologies & Bioresources, Inc.

Nexvet Biopharma PLC

nice Neotech Medical Systems Pvt. Ltd.

Northwell Health  Inc.

Novartis AG

OpenLink Financial LLC

Opexa Therapeutics, Inc.

Otsuka Pharmaceutical Co.  Ltd.

Owens & Minor, Inc.

Panacos Pharmaceuticals, Inc.

PELICAN HEALTHCARE LTD

Pfizer Inc.

Pharma Mar SA

Phillips

Phoenix Medical Systems Pvt. Ltd.

Polymer Technology Systems  Inc.

Progyny Inc.

Quanterix Corp.

Quest Diagnostics, Inc.

Smith & Nephew Plc

Spectrum Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Windtree Therapeutics, Inc.

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store